DiagnosTear Overview
DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome. The company is developing an assay designed to facilitate the diagnosis, treatment, and monitoring of dry eye syndrome by examining certain parameters in tear fluid. DiagnosTears TeaRx assay is based on various reagents that create color reactions when coming into contact with tear film, allowing for a semi-quantitative assessment of the parameters that define the syndrome. Information on the parameters assists in the diagnosis of the syndrome and enables a better, more informed selection of treatment and monitoring options. TeaRx enables the monitoring and screening of the condition by examining up to five different varieties of tear fluid. The test is carried out through the use of a simple device that is placed under the lower eyelid to absorb the tear fluid. DiagnosTear is an XLVision Sciences company and a fully owned subsidiary of BioLight.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units
DiagnosTear Technologies Inc., an ophthalmic company, announced an increase in its non-brokered private placement offering to up to 2,000,000 units, aiming to raise $1,000,000. Each unit consists of one common share and one warrant, with the warrant exercisable at $1.00 for 18 months. The funds will support working capital and general corporate purposes. The offering is expected to close by November 5, 2025, subject to compliance with Canadian Securities Exchange requirements. DiagnosTear is known for its TeaRx™ technology, a diagnostic platform for ophthalmic pathologies, including a CE-IVD and Israeli MoH-approved test for Dry Eye Syndrome. The product is not yet FDA-cleared, and the company is developing additional tests for other eye conditions.
PIPE/PO
growth-positive
DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
DiagnosTear Technologies Inc. has announced the listing of its common shares on the Frankfurt Stock Exchange, marking a significant milestone in its expansion into European capital markets. This move is expected to enhance the companys visibility and trading liquidity, particularly in a region known for its focus on healthcare innovation. Additionally, DiagnosTear has engaged bullVestor Medien GmbH for marketing services to support its presence in the German market. The agreement with bullVestor, valued at €300,000, aims to increase awareness and engagement with European investors. The listing and marketing efforts are part of DiagnosTears strategy to strengthen its international presence and foster relationships with institutional and retail investors across Europe.
Public TradingPartners
growth-positive
DiagnosTear Technologies Announces $700,000 Private Placement to Enhance Financial Position - TipRanks.com
DiagnosTear Technologies, Inc., a company specializing in ophthalmic diagnostic solutions, announced a non-brokered private placement to raise $700,000 through the sale of 1,400,000 units at $0.50 per unit. Each unit includes one common share and one warrant, exercisable at $1.00 within 18 months. The funds will be used for working capital and general corporate purposes, supporting the companys development of diagnostic solutions in the ophthalmic industry. DiagnosTears flagship technology, TeaRx™, is a diagnostic platform for rapid, Point-of-Care Testing of ophthalmic pathologies, and the company is expanding its pipeline to include tests for various eye conditions.
Investment
growth-positive
Canadian Securities Exchange Reports 2024 Performance Figures
The Canadian Securities Exchange (CSE) reported strong growth in financing activity for 2024, with a significant increase in the number of financings and total capital raised compared to 2023. The CSE introduced 45 new corporate listings, including 11 IPOs, and completed 1,140 financings raising $2.1 billion. Trading activity also increased, with 13.1 billion shares traded and a trading value of $4.0 billion. The CSEs membership in the World Federation of Exchanges and participation in the upcoming Vancouver Resource Investment Conference highlight its efforts to strengthen its position. The CSEs growth is attributed to interest rate cuts and high metal prices, which have fueled investor interest.
Public Trading
growth-positive
Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
DiagnosTear Technologies Inc., an Israel-based ophthalmic company, has been listed on the Canadian Securities Exchange (CSE) under the symbol DTR. The company specializes in developing and commercializing diagnostic solutions for eye diseases, focusing on its TeaRx™ technology for rapid, point-of-care testing through tear fluid. DiagnosTear aims to become a global leader in ocular disease diagnostics, particularly for conditions like dry eye and red eye. The listing on the CSE marks a significant step in the companys growth, providing access to public capital markets and enhancing its global liquidity.
Public Trading
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $4.55M |
| Last funding | $700K |
| Stage | Public |
| Rounds | 4 |
| Investors | 2 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | bio-light.co.il/diagnos-tear/ |
Locations
Kiryat Atidim, Tel Aviv-Yafo, Israel
Photos & Videos
1 item(s)
